Skip to main content

Oregon State Flag An official website of the State of Oregon »

Oregon.gov Homepage

Drug reviews

SURVEY LINKS (Request for information about drugs under review) 2025 Oregon PDAB drug review resources

2025 Oregon PDAB drug review documents, videos, minutes

Drug review group Review documents Meeting video Meeting minutes
Vraylar, Entresto, Ajovy, Emgality, Nurtec, Ubrelvy
 July 16, 2025 July 16, 2025 July 16, 2025
Trelegy, Eliquis, Xarelto, Cosentyx, Creon Aug. 20, 2025 Aug. 20, 2025 Aug. 20, 2025
Jardiance, Mounjaro, Ozempic, Rybelsus, Trulicity Sept. 17, 2025 Sept. 17, 2025 Sept. 17, 2025
Insulin products: Basaglar KwikPen, Insulin Glardine-yfgn, Lantus, Lantus SolorStar, Semglee-yfgn, Toujeo Max SolarStar, Toujeo SoloStar
Oct. 15, 2025 Oct. 15, 2025 Oct. 15, 2025

Document links will be updated one week before board meetings Video links will be updated the day after board meetings Meeting minute links will be updated after board approval the following month

August 20, 2025 Board Meeting Resources

July 16, 2025 Board Meeting Resources

June 18, 2025 Board Meeting Resources

April 16, 2025 Board Meeting Resources

March 19, 2025 Board Meeting Resources

February 19, 2025 Board Meeting Resources

January 15, 2025 Board Meeting Resources


About Oregon PDAB drug reviews: The Prescription Drug Affordability Board conducts annual drug reviews for identified drugs and insulin products as directed by ORS 646A.694 using criteria established in Oregon law. In a drug review, the board considers prescription drugs, applies criteria and determines whether the drugs may cause affordability challenges for Oregonians and health care systems in the state. The board compiles a list of nine prescription drugs and at least one insulin product for the Oregon Legislature. The criteria includes feedback from people impacted by the drug.

The board begins with a list of eligible prescription drugs provided by the Drug Price Transparency (DPT) program pursuant to ORS 646A.694. The board also uses insulin information from the Oregon Health Authority All Claims All Payers (APAC) data base. The DPT list comes from information submitted by manufacturers and insurance companies to the Department of Consumer Business Services. The board narrows the lists to a subset list and then reviews the insulin products and prescription drugs one at a time.

The board adopted two rules in 2023 to guide the board drug review process. OAR 925-200-0010 criteria for board selection of the subset list of drugs and OAR 925-200-0020 criteria for drug reviews.